Mutation-specific effects of NRAS oncogenes in colorectal cancer cells.
Inflammation
Interleukins
Protein multiplex analysis
RAS-Responsive genes
Signal transduction
Journal
Advances in biological regulation
ISSN: 2212-4934
Titre abrégé: Adv Biol Regul
Pays: England
ID NLM: 101572336
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
07
12
2020
accepted:
21
12
2020
pubmed:
13
1
2021
medline:
28
10
2021
entrez:
12
1
2021
Statut:
ppublish
Résumé
In colorectal cancer (CRC), the prevalence of NRAS mutations (5-9%) is inferior to that of KRAS mutations (40-50%). NRAS mutations feature lately during tumour progression and drive resistance to anti-EGFR therapy in KRAS wild-type tumours. To elucidate specific functions of NRAS mutations in CRC, we expressed doxycycline-inducible G12D and Q61K mutations in the CRC cell line Caco-2. A focused phospho-proteome analysis based on the Bio-Plex platform, which interrogated the activity of MAPK, PI3K, mTOR, STAT, p38, JNK and ATF2, did not reveal significant differences between Caco-2 cells expressing NRAS
Identifiants
pubmed: 33431353
pii: S2212-4926(20)30089-0
doi: 10.1016/j.jbior.2020.100778
pii:
doi:
Substances chimiques
Chemokines
0
Cytokines
0
Membrane Proteins
0
GTP Phosphohydrolases
EC 3.6.1.-
NRAS protein, human
EC 3.6.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100778Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.